14 September 2023  
EMA/405326/2023  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Kalydeco 
ivacaftor 
On 14 September 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Kalydeco. The marketing authorisation holder for this medicinal product is Vertex Pharmaceuticals 
(Ireland) Limited. 
The CHMP adopted a new indication for Kalydeco granules to include treatment of cystic fibrosis (CF) in 
children aged between 2 and 6 years in a combination regimen with ivacaftor/tezacaftor/elexacaftor. For 
information, the full indications for Kalydeco granules will be as follows:2 
•  As monotherapy for the treatment of infants aged at least 4 months, toddlers and children 
weighing 5 kg to less than 25 kg with cystic fibrosis (CF) who have an R117H CFTR mutation 
or one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, 
G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. 
• 
In a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of 
cystic fibrosis (CF) in paediatric patients aged 2 to less than 6 years who have at 
least one F508del mutation in the CFTR gene. 
For information, the indications for Kalydeco tablets remain unchanged and are provided in the summary 
of product characteristics (SmPC). 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR) and will be available in all official European Union languages after a decision on this change to the 
marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
 
